Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies

Levenga, Tjakiena H; Timmer-Bonte, Johanna N.H.

doi:10.1111/j.1365-2141.2007.06653.x

Cited by 12 publications

(4 citation statements)

References 60 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding may prove to be of importance in identifying risk factors for mortality. This nil mortality rate among published non‐Hodgkin’s lymphoma patients is likely because they receive less intensive chemotherapy regimens, resulting in shorter duration of grade 4 neutropenia 34–36 . As has been stressed by Anatoliotaki et al.…”

Section: Discussionmentioning

confidence: 98%

“…This nil mortality rate among published non-HodgkinÕs lymphoma patients is likely because they receive less intensive chemotherapy regimens, resulting in shorter duration of grade 4 neutropenia. [34][35][36] As has been stressed by Anatoliotaki et al [37], the resolution of neutropenia is essential for the recovery of Rhodotorula fungaemia. Interestingly, in this issue of the journal, we report a patient with multiple myeloma who presented two episodes of CVCrelated Rhodotorula fungaemia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and outcome of Rhodotorula infection in haematological patients

García‐Suárez

Gómez-Herruz

Cuadros

et al. 2010

Mycoses

View full text Add to dashboard Cite

Rhodotorula spp. are emergent opportunistic pathogens, particularly in haematological patients. However, no systematic review of this infection has been undertaken in this high-risk patient group. The aim of this study was to review all reported cases of Rhodotorula infection to determine the epidemiology and outcome of this infection in this high-risk population. The 29 reported cases were fungaemias. The most common underlying haematological disorder was the presence of acute leukaemia (65.5%). Rhodotorula mucilaginosa was the species found more frequently (79.3%). Most cases (58.6%) had several risk factors (≥ 3) simultaneously. The most common predisposing factors were the presence of central venous catheter (CVC, 100%) and neutropenia (62.1%). A substantial number of patients (81.5%) received antifungal treatment with amphotericin B. The overall mortality was higher (13.8%) than that described in non-haematological patients (5.8% in solid-organ neoplasms and 9% in AIDS or other chronic diseases). Patients with acute leukaemia had a higher mortality rate (15.7%) than patients with non-Hodgkin's lymphoma (0%). Our data suggest that patients with acute leukaemia might be managed as high-risk patients and intensive measures might be taken. In addition, it appears that the subgroup of patients without acute leukaemia have a good outcome and might be managed as low-risk patients with a less intensive approach.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Epidemiology and outcome of Rhodotorula infection in haematological patients

García‐Suárez

Gómez-Herruz

Cuadros

et al. 2010

Mycoses

View full text Add to dashboard Cite

show abstract

“…154,170,171 Likewise, in patients receiving myelosuppressive treatment, no indication for Gor GM-CSF has been clearly established, especially in higher-risk patients in whom these agents could potentially increase the risk of AML progression.…”

Section: A Toma Et Almentioning

confidence: 99%

Infections in myelodysplastic syndromes

et al. 2012

View full text Add to dashboard Cite

Myelodysplastic syndromes are associated with a risk of severe infections. While neutropenia is likely to be the main predisposing factor, several other immune defects have been reported, including impaired neutrophil function, B-, T-and NK-cell defects and the possible consequences of iron overload due to red blood cell transfusions. The advanced age of most patients, their frequent comorbidities, and the fact that drugs such as hypomethylating agents and lenalidomide, which are effective in myelodysplastic syndromes but can transiently worsen neutropenia, may increase the risk of infection and their severity in this context. The majority of infections in myelodysplastic syndromes are bacterial, while the incidence of fungal infections is not well known and viral infections seem to be rare. No prophylactic measures against infections have demonstrated efficacy in myelodysplastic syndromes. However, pending more data, we propose here some recommendations for the management of patients with myelodysplastic syndromes. In the future, an important contribution can be made by prospective trials testing the efficacy of prophylactic and therapeutic approaches to infection in these patients, especially in the context of the new drugs available for myelodysplastic syndromes. ABSTRACTand respective bacterial, fungal, and viral causes of infection in MDS. Most of these data are retrospective. Some are compromised by inconsistencies in the definition of the infectious events or, although taken from therapeutic trials, may be biased by patient eligibility criteria. In a recent US retrospective series of 273 untreated low-or intermediate-1 risk MDS patients who died in the period from 1980 to 2004, infection was the primary cause of death, accounting for 38% of the total, followed by AML transformation (15%) and hemorrhage (13%).9 Pneumonia was the most common infection, responsible for 40% of infectious deaths. Infection, mostly of a bacterial origin, was microbiologically documented in 30% of the cases of pneumonia in these MDS patients. As this study covered three decades, it was possible to show a significant decrease in the incidence of infectious deaths over time, likely attributable to improved supportive care. Another US survey of the Medicare population (an insurance covering more than 97% of all US citizens aged 65 years or over) indicated that, in a population of 1.3 million people over the age of 65 years followed between the years 2003 and 2005, patients with MDS had a higher prevalence of infections than the non-MDS Medicare population (22.5% vs. 6.

show abstract

“…Acute leukaemia patients receiving intensive chemotherapy experience a period of severe, treatment-induced pancytopenia often lasting 1-3 weeks depending on the treatment regimen [1][2][3][4]. The therapeutic use of hematopoietic growth factors has only limited effects on the duration of severe neutropenia [5], and the treatmentrelated mortality observed in this patient group is mainly due to the neutropenia, with a high risk of complicating bacterial and fungal infections [3]. The patients also develop severe thrombocytopenia.…”

mentioning

confidence: 99%